Search Results - "Bataller, R. de las Penas"

SEOM clinical guidelines for anaemia treatment in cancer patients (2020) by Escobar Álvarez, Y., de las Peñas Bataller, R., Perez Altozano, J., Ros Martínez, S., Sabino Álvarez, A., Blasco Cordellat, A., Brozos Vázquez, E., Corral Jaime, J., García Escobar, I., Beato Zambrano, C.

“…Anaemia is defined by the presence of haemoglobin (Hb) levels < 13 g/dL in men and 12 g/dL in women. Up to 39% of cancer patients present it at the time of…”
Get full text

Correction to: SEOM clinical guidelines for anaemia treatment in cancer patients (2020) by Escobar Álvarez, Y., de las Peñas Bataller, R., Perez Altozano, J., Ros Martínez, S., Sabino Álvarez, A., Blasco Cordellat, A., Brozos Vázquez, E., Corral Jaime, J., García Escobar, I., Beato Zambrano, C.

Get full text

Updated analysis of the national registry of nervous system tumours in Spain (RETSINE). RETSINE: National registry of nervous system tumours of the Spanish research group in neuro-oncology (GEINO) and Spanish infrequent and orphan tumours group (GETHI) by Ceballos Lenza, I., Perez Segura, P., Salgado, M.A.V., del barco, S., Gallego, O., Quintanar, T., Ivars, M.A., Fernandez Perez, I., García-Piñon, F., de las Penas Bataller, R.

Get full text

412P - Updated analysis of the national registry of nervous system tumours in Spain (RETSINE). RETSINE: National registry of nervous system tumours of the Spanish research group in neuro-oncology (GEINO) and Spanish infrequent and orphan tumours group (GETHI) by Ceballos Lenza, I., Perez Segura, P., Salgado, M.A.V., del barco, S., Gallego, O., Quintanar, T., Ivars, M.A., Fernandez Perez, I., García-Piñon, F., de las Penas Bataller, R.

“…The Spanish Research Group in Neuro-oncology (GEINO) and Spanish Infrequent and Orphan Tumors Group (GETHI) initiated a Nervous System Tumors Registry…”
Get full text

EP-1025 RESCUE TREATMENT FOR HIGH GRADE GLIOMAS THROUGH HYPOFRACTIONATED RT+ BEVACIZUMAB. EXPERIMENTAL STUDY by Vidal, V. González, Moreno, A. Conde, Almendros, P, De Las Peñas Bataller, R, Albiach, C. Ferrer

Get full text

412PUpdated analysis of the national registry of nervous system tumours in Spain (RETSINE). RETSINE: National registry of nervous system tumours of the Spanish research group in neuro-oncology (GEINO) and Spanish infrequent and orphan tumours group (GETHI) by Ceballos Lenza, I, Perez Segura, P, Salgado, M A V, del barco, S, Gallego, O, Quintanar, T, Ivars, M A, Fernandez Perez, I, García-Piñon, F, de las Penas Bataller, R

“…Abstract Background The Spanish Research Group in Neuro-oncology (GEINO) and Spanish Infrequent and Orphan Tumors Group (GETHI) initiated a Nervous System…”
Get full text

1069P A multicenter phase II study of nivolumab combined with ipilimumab in patients with pediatric solid tumours in adulthood (GETHI021) by Rubio, X. Mielgo, Diaz-Beveritge, R., Sanchez, J.M. Sepulveda, Pineda, E., Salgado, M.Á. Vaz, Lecumberri, M.J., Valverde, C., Castro, R. Lopez, López, C., Echaburu, J.A. Virizuela, Salas, N. Rodriguez, Bataller, R. de las Penas, Lopez, R. Lopez, Rodriguez, J. Medina, Rodriguez-Antona, C., Berraondo, P., Rodriguez-Moreno, J.F., Nuño, A. Hurtado, Sevillano, E., Garcia-Donas, J.

Get full text

398PD - Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial by Salgado, M.A.V., Sepulveda Sanchez, J.M., del barco, S., Pineda, E., Fuster, J., Navarro Martin, M., Herrero Ibañez, A., Alonso, M., Perez, J., Mesia, C., Munoz-Langa, J., de las Penas Bataller, R., Peralta, S., Olier, C., Pérez-Segura, P., Estival, A., Carrato, C., Saez, C., Gil, M.J., Balana, C.

“…Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01 trial (NCT02209948)…”
Get full text

BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial by Massuti Sureda, B., Sanchez Torres, J.M., Cobo Dols, M., Moran Bueno, M.T., Gonzalez-Larriba, J.L., Barneto Aranda, I.C., De Castro Carpeno, J., Iglesias, L., Muñoz, M.A., López Vivanco, G., Isla Casado, M.D., López, R., de las Penas Bataller, R., Rodriguez Abreu, D., Artal-Cortes, A., Esteban, E., Provencio, M., Pereira, E., Sanchez-Paya, J., Rosell, R.

Get full text

1461P - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) by Guirado, M., Majem, M., Massuti Sureda, B., de las Penas Bataller, R., Ortega Granados, A.L., Isla Casado, M.D., Domine Gomez, M., Marse Fabregat, R., Sala, M.A., Paredes Lario, A., Moran Bueno, M.T., Vazquez Estevez, S., Coves Sarto, J., Gonzalez-Larriba, J.L., Sanchez Torres, J.M., Vicente, D., Farre Bernado, N., Fernandez-Fornos, L., Varcarcel, F., Provencio, M.

“…CT-RT is the standard treatment for unresectable LA-NSCLC. P plus vinorelbine is widely used. Metronomic CT is a frequent administration of low doses of CT…”
Get full text

NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) by Guirado, M., Majem, M., Massuti Sureda, B., de las Penas Bataller, R., Ortega Granados, A.L., Isla Casado, M.D., Domine Gomez, M., Marse Fabregat, R., Sala, M.A., Paredes Lario, A., Moran Bueno, M.T., Vazquez Estevez, S., Coves Sarto, J., Gonzalez-Larriba, J.L., Sanchez Torres, J.M., Vicente, D., Farre Bernado, N., Fernandez-Fornos, L., Varcarcel, F., Provencio, M.

Get full text

1461PNORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) by Guirado, M, Majem, M, Massuti Sureda, B, de las Penas Bataller, R, Ortega Granados, A L, Isla Casado, M D, Domine Gomez, M, Marse Fabregat, R, Sala, M A, Paredes Lario, A, Moran Bueno, M T, Vazquez Estevez, S, Coves Sarto, J, Gonzalez-Larriba, J L, Sanchez Torres, J M, Vicente, D, Farre Bernado, N, Fernandez-Fornos, L, Varcarcel, F, Provencio, M

“…Abstract Background CT-RT is the standard treatment for unresectable LA-NSCLC. P plus vinorelbine is widely used. Metronomic CT is a frequent administration of…”
Get full text

1439PD - BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial by Massuti Sureda, B., Sanchez Torres, J.M., Cobo Dols, M., Moran Bueno, M.T., Gonzalez-Larriba, J.L., Barneto Aranda, I.C., De Castro Carpeno, J., Iglesias, L., Muñoz, M.A., López Vivanco, G., Isla Casado, M.D., López, R., de las Penas Bataller, R., Rodriguez Abreu, D., Artal-Cortes, A., Esteban, E., Provencio, M., Pereira, E., Sanchez-Paya, J., Rosell, R.

“…Post-operative platinum-based chemotherapy is the standard of care for resected NSCLC with nodal involvement. Expression of genes involved in DNA repair may…”
Get full text

398PDExtending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial by Salgado, M A V, Sepulveda Sanchez, J M, del barco, S, Pineda, E, Fuster, J, Navarro Martin, M, Herrero Ibañez, A, Alonso, M, Perez, J, Mesia, C, Munoz-Langa, J, de las Penas Bataller, R, Peralta, S, Olier, C, Pérez-Segura, P, Estival, A, Carrato, C, Saez, C, Gil, M J, Balana, C

“…Abstract Background Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01…”
Get full text

Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial by Salgado, M.A.V., Sepulveda Sanchez, J.M., del barco, S., Pineda, E., Fuster, J., Navarro Martin, M., Herrero Ibañez, A., Alonso, M., Perez, J., Mesia, C., Munoz-Langa, J., de las Penas Bataller, R., Peralta, S., Olier, C., Pérez-Segura, P., Estival, A., Carrato, C., Saez, C., Gil, M.J., Balana, C.

Get full text

1439PDBRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial by Massuti Sureda, B, Sanchez Torres, J M, Cobo Dols, M, Moran Bueno, M T, Gonzalez-Larriba, J L, Barneto Aranda, I C, De Castro Carpeno, J, Iglesias, L, Muñoz, M A, López Vivanco, G, Isla Casado, M D, López, R, de las Penas Bataller, R, Rodriguez Abreu, D, Artal-Cortes, A, Esteban, E, Provencio, M, Pereira, E, Sanchez-Paya, J, Rosell, R

“…Abstract Background Post-operative platinum-based chemotherapy is the standard of care for resected NSCLC with nodal involvement. Expression of genes involved…”
Get full text